IKBKB and melanoma: Consequently, administration of an IKKβ inhibitor after tumour vaccination in a mouse melanoma model enhanced the CTL-dependent anti-tumour response and delayed tumour growth, identifying IKKβ as a potential druggable immune checkpoint.